Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT04703244

Development of Patient Derived Xenografts (PDX) in Patients With Breast Cancer

Sponsor: Mayo Clinic

View on ClinicalTrials.gov

Summary

Breast cancer patients who undergo neoadjuvant systemic therapy and have residual breast cancer identified at the time of surgery exhibit a high (\>50%) risk of future life-threatening recurrences and death.

Official title: Development of Patient Derived Xenografts (PDX) in Patients With Breast Cancer Who Have Residual Disease After Neoadjuvant Systemic Therapy

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

OBSERVATIONAL

Enrollment

999

Start Date

2021-01-13

Completion Date

2042-01-15

Last Updated

2026-03-03

Healthy Volunteers

No

Interventions

PROCEDURE

chemotherapy or endocrine therapy for breast cancer

Collect blood and leftover surgical tissue from patients with breast cancer remaining after chemotherapy or endocrine therapy is completed.

Locations (1)

Mayo Clinic

Rochester, Minnesota, United States